Cat. No. | Product name | CAS No. |
DC12376 |
AZ304
Featured
AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively. |
942507-42-8 |
DC10994 |
Balamapimod
Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.. |
863029-99-6 |
DC12278 |
Belvarafenib
Featured
Belvarafenib is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. |
1446113-23-0 |
DC7718 |
B-Raf IN 1
Featured
B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM). |
950736-05-7 |
DC8921 |
B-Raf inhibitor 1
Featured
B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respectively. |
1093100-40-3 |
DC7008 |
BRAF inhibitor
Featured
BRAF inhibitor is a potent BRAF inhibitor. |
918505-61-0 |
DC10005 |
CCT196969
Featured
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. |
1163719-56-9 |
DC8777 |
CEP-32496 hydrochloride
CEP-32496 Hcl is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. |
1227678-26-3 |
DC8196 |
CEP-32496
Featured
CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. |
1188910-76-0 |
DC5149 |
Dabrafenib
Featured
Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Phase 3. |
1195765-45-7 |
DC4103 |
Dabrafenib Mesylate
Featured
Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. |
1195768-06-9 |
DC3102 |
GDC-0879
GDC-0879 is a novel potent, selective B-Raf inhibitor for B-RafV600E with IC50 of 0.13 nM. |
905281-76-7 |
DC8810 |
GW-5074
Featured
GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms. |
220904-83-6 |
DC8362 |
L-779,450
Featured
L-779,450 is a potent, ATP-competitive Raf (Raf kinase) inhibitor (IC50 = 10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively. |
303727-31-3 |
DC7018 |
LGX-818(Encorafenib)
Featured
LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity. |
1269440-17-6 |
DC10099 |
BGB283
Lifirafenib(BGB-283) is a Novel potent and selective RAF Kinase and EGFR inhibitor. |
1446090-77-2 |
DC10828 |
LXH254
Featured
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
1800398-38-2 |
DC8344 |
LY3009120
Featured
LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity. |
1454682-72-4 |
DC8727 |
PF-04880594
Featured
PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively. |
1111636-35-1 |
DC1071 |
Vemurafenib (PLX4032)
Featured
PLX4032 (Vemurafenib, RG7204, Zelboraf, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM. |
918504-65-1 |
DC6301 |
PLX-4720
Featured
PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf. |
918505-84-7 |
DC9814 |
PLX7904(PB04)
Featured
PLX7904(PB04) is a potent and selective paradox-breaker RAF inhibitor. |
1393465-84-3 |